Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
New York Medical College manages a company patent portfolio in the Biotechnology & Pharmaceuticals technology area with 2 pending office actions. This volume of 2 pending office actions indicates that the college is currently pursuing multiple patent applications. The presence of these two active matters suggests a multi-track prosecution strategy within the pharmaceutical sector.
The prosecution is handled by 2 distinct examiners across 2 distinct art units. This 1 to 1 ratio between the 2 pending office actions and the 2 distinct examiners means that each matter is being reviewed by a different individual. Furthermore, because there are 2 distinct art units, each of the 2 pending office actions is being evaluated within a different specialized group at the patent office.
SULLIVAN, DENNIS JOHN is the busiest examiner for the college, with 1 busiest examiner pending action. Given that the total number of pending office actions is 2, this examiner is responsible for one of the active matters. The fact that there are 2 distinct examiners for 2 actions confirms that the workload is split evenly, with each examiner managing exactly 1 pending action.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SULLIVAN, DENNIS JOHN | 1 | 57.3% | +49.1% |
| BUTTICE, AUDREY L | 1 | 47.9% | +25.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17672004 | USE OF 12-LIPOXYGENASE INHIBITORS IN THE TREATMENT OF COVID-19 | BUTTICE, AUDREY L | 131d overdue |
| 18314438 | MODULATION OF BETA CELL REGENERATION THROUGH GPR75 SIGNALING | SULLIVAN, DENNIS JOHN | 84d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17672004 | USE OF 12-LIPOXYGENASE INHIBITORS IN THE TREATMENT OF COVID-19 | BUTTICE, AUDREY L | 131d overdue |
| 18314438 | MODULATION OF BETA CELL REGENERATION THROUGH GPR75 SIGNALING | SULLIVAN, DENNIS JOHN | 84d |
| Art Unit | Apps |
|---|---|
| 1642 | 1 |
| 1683 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18314438 | MODULATION OF BETA CELL REGENERATION THROUGH GPR75 SIGNALING | SULLIVAN, DENNIS JOHN | 1642 | §103§112 | Final Rejection | 84d | Pending | May 09, 2023 |
| 17672004 | USE OF 12-LIPOXYGENASE INHIBITORS IN THE TREATMENT OF COVID-19 | BUTTICE, AUDREY L | 1683 | §102§103 | Non-Final OA | 131d overdue | Pending | Feb 15, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial